Determine the necessary mass, volume, or concentration for preparing a solution.
≥98% ベースライン干渉を最小限に抑える必要がある、感度の高いクロマトグラフィーおよび分析ワークフロー向け。
Protected from light,Store at -80°C Dry ice packs + Cold packs に出荷。正確な仕様については、ロット固有の COA をご確認ください。
SDS、COA、データシート、仕様書をダウンロードできます。ロット固有の COA はロット番号検索で入手可能です。
クロマトグラフィー、有機合成、クロスカップリング反応に関する 0 件の査読済み論文で引用されています。
BSc3094 is a Tau aggregation inhibitor. BSc3094 can be used for the research of Alzheimer's disease (AD)
In Vivo
BSc3094 (3 mg/kg; i.v.) direct intraventricular administration reduces sarkosyl-insoluble Tau . BSc3094 (0.075~1.5 mM; intraventricular administration) reduces the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70% . BSc3094 reverses the pre-synaptic impairment in organotypic hippocampal slices from pro-aggregant mice, by reversing the pairedpulse depression observed in non-treated pro-aggregant Tau slices after applying a paired-pulse stimulus of the Schaffer collaterals. BSc3094 reverses the increase in Tau phosphorylation levels in rTg4510 mice down to control level. BSc3094 partially reversed the memory deficits in rTg4510 mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 3 mg/kg Administration: I.v. Result: Direct intraventricular administration reduced sarkosyl-insoluble Tau. Animal Model: rTg4510 mice Dosage: 0.075~1.5 mM Administration: Intraventricular administration Result: Reduced the levels of sarkosyl-insoluble Tau in cortical extracts by ≈70%.
Form:Solid
IC50& Target:Tau aggregation
危険性、取扱い、保管、および規制遵守を網羅した包括的な文書。
<<<<<<< HEAD SDS をダウンロード → ======= SDS をダウンロード → >>>>>>> release248-p3| 溶解度 | DMSO : 33.33 mg/mL (87.62 mM; Need ultrasonic) |
|---|